Quantumzyme Corp. (QGAI) — SEC Filings
Quantumzyme Corp. (QGAI) — 4 SEC filings. Latest: 10-Q (Dec 15, 2025). Sentiment: bearish. Includes 2 10-Q, 1 10-K/A, 1 10-K. Overall sentiment: bearish.
View Quantumzyme Corp. on SEC EDGAR
Overview
Quantumzyme Corp. (QGAI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Dec 15, 2025: Quantumzyme Corp. (QGAI) reported a net loss of $49,868 for the quarter ended October 31, 2025, a 23.9% improvement from the $65,523 net loss in the same period of 2024. The company generated no revenue in either period. Operating expenses decreased to $39,196 from $60,934 year-over-year, primarily
Sentiment Summary
Across 4 filings, the sentiment breakdown is: 2 bearish, 2 mixed. The dominant filing sentiment for Quantumzyme Corp. is bearish.
Filing Type Overview
Quantumzyme Corp. (QGAI) has filed 2 10-Q, 1 10-K/A, 1 10-K with the SEC between Jun 2025 to Dec 2025.
Recent SEC Filings (4)
| Date | Form | Description | Risk |
|---|---|---|---|
| Dec 15, 2025 | 10-Q | Quantumzyme's Cash Dries Up Amidst Persistent Losses | high |
| Nov 17, 2025 | 10-K/A | Quantumzyme Amends 10-K for Audit Report, Executive Pay Correction | medium |
| Nov 13, 2025 | 10-K | Quantumzyme Targets Green Ibuprofen Production, Eyes Broader Biocatalysis Market | high |
| Jun 20, 2025 | 10-Q | Quantumzyme Narrows Loss to $1K, Still Pre-Revenue | high |
Risk Profile
Risk Assessment: Of QGAI's 4 recent filings, 3 were flagged as high-risk, 1 as medium-risk, and 0 as low-risk. The overall risk profile suggests elevated risk that warrants close monitoring.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$49,868 |
| EPS | $0.00 |
| Debt-to-Equity | N/A |
| Cash Position | $184 |
| Operating Margin | N/A |
| Total Assets | $184 |
| Total Debt | $490,769 |
Key Executives
- Naveen Krishna Rao Kulkarni
- Sandra (Demeria) Brossart
- Naveen Krishnarao Kulkarni
Industry Context
Quantumzyme Corp. operates in a highly competitive biotechnology or life sciences sector, characterized by long development cycles, significant R&D investment, and high failure rates. Companies in this space often rely heavily on external funding, including venture capital and public markets, to sustain operations until a product reaches commercialization. The industry faces stringent regulatory hurdles and requires continuous innovation to stay relevant.
Top Tags
Biotechnology (4) · Small Cap (2) · High Risk (2) · Enzyme Engineering (2) · API Production (2) · Going Concern (1) · Net Loss (1) · No Revenue (1) · Cash Depletion (1) · 10-K/A (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash balance | $184 | As of October 31, 2025, down from $584 on July 31, 2025, indicating severe liquidity issues. |
| Net loss | $49,868 | For the quarter ended October 31, 2025, a persistent loss with no revenue. |
| Accumulated deficit | $5,686,435 | As of October 31, 2025, highlighting significant historical losses. |
| Sales revenue | $0 | For both the quarters ended October 31, 2025, and 2024, indicating no operational income. |
| Notes payable | $268,594 | As of October 31, 2025, an increase from $249,081 on July 31, 2025, contributing to rising liabilities. |
| Net cash used in operating activities | $19,913 | For the quarter ended October 31, 2025, further depleting cash reserves. |
| Common shares outstanding | 38,962,050 | As of December 15, 2025, and October 31, 2025. |
| Total operating expenses | $39,196 | For the quarter ended October 31, 2025, a decrease from $60,934 in the prior year, but still significant without revenue. |
| Stock-based compensation | $54,500 | Added for Mr. Naveen Krishnarao Kulkarni for fiscal year 2024 |
| Market value of non-affiliate common equity | $4,327,050 | As of the last business day of the most recently completed second fiscal quarter |
| Common stock outstanding | 38,962,050 | As of November 10, 2025 |
| Fiscal year end | July 31, 2025 | Period covered by the 10-K/A |
| 10-K/A filing date | November 17, 2025 | Date of the amendment filing |
| Market Value of Non-Affiliate Equity | $4.33M | Indicates a very small market capitalization and potential for high volatility. |
| Common Stock Outstanding | 38.96M | Total shares outstanding as of November 10, 2025. |
Frequently Asked Questions
What are the latest SEC filings for Quantumzyme Corp. (QGAI)?
Quantumzyme Corp. has 4 recent SEC filings from Jun 2025 to Dec 2025, including 2 10-Q, 1 10-K/A, 1 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of QGAI filings?
Across 4 filings, the sentiment breakdown is: 2 bearish, 2 mixed. The dominant sentiment is bearish.
Where can I find Quantumzyme Corp. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Quantumzyme Corp. (QGAI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Quantumzyme Corp.?
Key financial highlights from Quantumzyme Corp.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for QGAI?
The investment thesis for QGAI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Quantumzyme Corp.?
Key executives identified across Quantumzyme Corp.'s filings include Naveen Krishna Rao Kulkarni, Sandra (Demeria) Brossart, Naveen Krishnarao Kulkarni.
What are the main risk factors for Quantumzyme Corp. stock?
Of QGAI's 4 assessed filings, 3 were flagged high-risk, 1 medium-risk, and 0 low-risk.
What are recent predictions and forward guidance from Quantumzyme Corp.?
Forward guidance and predictions for Quantumzyme Corp. are extracted from SEC filings as they are enriched.